Back to search
FDAFDA · Food and drugs·Recall number D-0208-2018

Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP, 7.5 mg/12.5 mg, 100-count bottle, Rx only, Distributed By: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5213-01.

Published January 17, 2018 · Recall initiated: December 14, 2017

Summary

FDA records drug Class II recall D-0208-2018, published January 17, 2018 and initiated December 14, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 4,969 bottles; Lot: Lot # 30229439A, Exp 12/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High out of specification test result for the Moexipril Diketopiperazine impurity was obtained during routine stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide in the USA
Lot
Lot # 30229439A, Exp 12/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP, 7.5 mg/12.5 mg, 100-count bottle, Rx only, Distributed By: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5213-01. recalled?

Yes. FDA published recall D-0208-2018 on January 17, 2018. Reported hazard: Failed Impurities/Degradation Specifications: High out of specification test result for the Moexipril Diketopiperazine impurity was obtained during routine stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter